Lentiviral vectors for immunization: An inflammatory field

Expert Review of Vaccines

Volumn 9, Issue 3, 2010, Pages 309-321

  Pincha, Mudita ^a   Sundarasetty, Bala Sai ^a   Stripecke, Renata ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cancer; Chronic infection; Clinical development; Dendritic cell; Immunotherapy; Lentiviral vector

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; DENDRITIC CELL VACCINE; EPITOPE; FLT3 LIGAND; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 4; LENTIVIRUS VECTOR; MELAN A; MONOPHENOL MONOOXYGENASE; MUCIN 1; NY ESO 1 ANTIGEN; OVALBUMIN; OX40 LIGAND; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GAMMA INTERFERON; UBIQUITIN; UBIQUITIN C; VACCINE;

ANTIGEN PRESENTING CELL; BIOSAFETY; BREAST CANCER; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; FOWLPOX VIRUS; GENE EXPRESSION; GLIOMA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; INFLUENZA; LIVER CELL CARCINOMA; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MELANOMA; MELANOMA B16; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION; REVIEW; SIMIAN VIRUS; TH1 CELL; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; VACCINATION; VIRAL VACCINES;

EID: 77949432625     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.9     Document Type: Review

References (76)

1. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996).
2. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72(11), 8463-8471 (1998).
3. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12), 9873-9880 (1998).
4. Dullaers M, Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J. Gene Med. 8(1), 3-17 (2006).
5. Stripecke R. Lentiviral vector-mediated genetic programming of mouse and human dendritic cells. Methods Mol. Biol. 506, 139-158 (2009).
6. Diao J, Smythe JA, Smyth C, Rowe PB, Alexander IE. Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. 6(5), 845-853 (1999).
7. Molnar-Kimber KL, Sterman DH, Chang M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy Phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9(14), 2121-2133 (1998).
8. Tan PH, Beutelspacher SC, Xue SA et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 105(10), 3824-3832 (2005).
9. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96(4), 1327-1333 (2000).
10. Koya RC, Kasahara N, Favaro PM et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J. Immunother. 26(5), 451-460 (2003).
11. Dullaers M, Breckpot K, van Meirvenne S et al. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. 10(4), 768-779 (2004).
12. Koya RC, Weber JS, Kasahara N et al. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum. Gene Ther. 15(8), 733-748 (2004).
13. Masurier C, Boutin S, Veron P, Bernard J, Danos O, Davoust J. Enhanced lentiviral transduction of monocyte-derived dendritic cells in the presence of conditioned medium from dying monocytes. Hum. Gene Ther. 18(2), 161-170 (2007).
14. Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 12(18), 2203-2213 (2001).
15. Metharom P, Ellem KA, Wei MQ. Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell. Mol. Immunol. 2(4), 281-288 (2005).
16. Koya RC, Kimura T, Ribas A et al. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol. Ther. 15(5), 971-980 (2007).
17. Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol. 172(4), 2232-2237 (2004).
18. Lopes L, Fletcher K, Ikeda Y, Collins M. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother. 55(8), 1011-1016 (2006).
19. Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther. 15(4), 393-404 (2004).
20. Wang B, He J, Liu C, Chang LJ. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 24(17), 3477-3489 (2006).
21. Mossoba ME, Walia JS, Rasaiah VI et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol. Ther. 16(3), 607-617 (2008).
22. Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97(1), 114-121 (2001).
23. Zarei S, Leuba F, Arrighi JF, Hauser C, Piguet V. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol. 109(6), 988-994 (2002).
24. Zarei S, Abraham S, Arrighi JF et al. Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J. Virol. 78(14), 7843-7845 (2004).
25. Buffa V, Negri DR, Leone P et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol. 19(4), 690-701 (2006).
26. Jirmo AC, Koya RC, Sundarasetty BS et al. Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8+ T cell responses. Vaccine 28(4), 922-933 (2010).
27. Kobayashi M, Takaori-Kondo A, Fukunaga K, Miyoshi H, Uchiyama T. Lentiviral gp34/OX40L gene transfer into dendritic cells facilitates alloreactive CD4+ T-cell response in vitro. Int. J. Hematol. 79(4), 377-383 (2004).
28. Pfeifer A, Kessler T, Yang M et al. Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. Mol. Ther. 3(3), 319-322 (2001).
29. Vanden Driessche T, Thorrez L, Naldini L et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100(3), 813-822 (2002).
30. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103(10), 3700-3709 (2004).
31. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 6(7), 1305-1312 (1999).
32. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 172(3), 1582-1587 (2004).
33. Rowe HM, Lopes L, Ikeda Y et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 13(2), 310-319 (2006).
34. Kimura T, Koya RC, Anselmi L et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol. Ther. 15(7), 1390-1399 (2007).
35. Lopes L, Dewannieux M, Gileadi U et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 82(1), 86-95 (2008).
36. Arce F, Rowe HM, Chain B, Lopes L, Collins MK. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol. Ther. 17(9), 1643-1650 (2009).
37. Kim JH, Majumder N, Lin H, Watkins S, Falo LD Jr, You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther. 16(11), 1255-1266 (2005).
38. Yang L, Yang H, Rideout K et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26(3), 326-334 (2008).
39. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21(11), 2891-2894 (1991).
40. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54(6), 777-785 (1988).
41. Dullaers M, van Meirvenne S, Heirman C et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13(7), 630-640 (2006).
42. He Y, Zhang J, Donahue C, Falo LD Jr. Skin-derived dendritic cells induce potent CD8+ T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24(5), 643-656 (2006).
43. Chapatte L, Colombetti S, Cerottini JC, Levy F. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res. 66(2), 1155-1160 (2006).
44. Esslinger C, Chapatte L, Finke D et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. J. Clin. Invest. 111(11), 1673-1681 (2003).
45. Liu Y, Peng Y, Mi M et al. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J. Immunol. 182(10), 5960-5969 (2009).
46. Levine BL, Humeau LM, Boyer J et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl Acad. Sci. USA 103(46), 17372-17377 (2006).
47. Lemiale F, Korokhov N. Lentiviral vectors for HIV disease prevention and treatment. Vaccine 27(25-26), 3443-3449 (2009).
48. Buffa V, Negri DR, Leone P et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J. Gen. Virol. 87(Pt 6), 1625-1634 (2006).
49. Iglesias MC, Mollier K, Beignon AS et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol. Ther. 15(6), 1203-1210 (2007).
50. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 5(6), 619-628 (2005).
51. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
52. Mulligan MJ. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Curr. Infect. Dis. Rep. 11(5), 399-406 (2009).
53. Steinbrook R. One step forward, two steps back - will there ever be an AIDS vaccine? N. Engl. J. Med. 357(26), 2653-2655 (2007).
54. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205(1), 7-12 (2008).
55. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 343-355 (2003).
56. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4(4), 575-588 (2004).
57. Jacobs BL, Langland JO, Kibler KV et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84(1), 1-13 (2009).
58. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol. 3(5), 495-500 (1996).
59. Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).
60. Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060-3069 (2008).
61. Eder JP, Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6(5), 1632-1638 (2000).
62. Arlen PM, Gulley JL, Todd N et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174(2), 539-546 (2005).
63. Lindsey KR, Gritz L, Sherry R et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12(8), 2526-2537 (2006).
64. Humrich JY, Thumann P, Greiner S et al. Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. Eur. J. Immunol. 37(4), 954-965 (2007).
65. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954), 818-823 (2009).
66. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in four patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008).
67. Saenz DT, Loewen N, Peretz M et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J. Virol. 78(6), 2906-2920 (2004).
68. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol. Ther. 17(8), 1316-1332 (2009).
69. Yanez-Munoz RJ, Balaggan KS, MacNeil A et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12(3), 348-353 (2006).
70. Karwacz K, Mukherjee S, Apolonia L et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J. Virol. 83(7), 3094-3103 (2009).
71. Hu B, Yang H, Dai B, Tai A, Wang P. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum. Gene Ther. 20(12), 1652-1664 (2009).
72. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol. Ther. 12(4), 585-598 (2005).
73. Nasu Y, Saika T, Ebara S et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol. Ther. 15(4), 834-840 (2007).
74. de Felipe P. Skipping the co-expression problem: the new 2A "CHYSEL" technology. Genet. Vaccines Ther. 2(1), 13 (2004).
75. Barr SD, Ciuffi A, Leipzig J, Shinn P, Ecker JR, Bushman FD. HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. Mol. Ther. 14(2), 218-225 (2006).
76. Wang GP, Levine BL, Binder GK et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17(5), 844-850 (2009).